Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Letrozole + PF-07104091 + PF-07220060|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Letrozole||Femara||Letrozol||Aromatase Inhibitor 3||Femara (letrozole) is an aromatase inhibitor, which inhibits estrogen synthesis, and is approved for postmenopausal women with hormone receptor positive breast cancer (FDA.gov).|
|PF-07104091||PF 07104091|PF07104091||CDK2 Inhibitor 27||PF-07104091 inhibits CDK2, which may result in cell cycle arrest, induction of apoptosis, and inhibition of tumor cell proliferation (NCI Drug Dictionary).|
|PF-07220060||PF 07220060|PF07220060||CDK4 Inhibitor 16||PF-07220060 inhibits CDK4 and may lead to cell cycle arrest and inhibition of tumor cell proliferation (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05262400||Phase II||Letrozole + PF-07104091 + PF-07220060 Fulvestrant + PF-07104091 + PF-07220060 PF-07104091 + PF-07220060||A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors||Recruiting||USA | ESP||7|